drugset / Trial / NCT05757856
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
Timeline
- Start
- 2023-01-20
- Primary completion
- 2025-05-22
- Completion
- 2025-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NDX-3315 | Unknown | — | Oral |
| Subject | NDX-3324 | Unknown | — | Oral |